Kezar Life Sciences climbs after FDA lifts clinical hold on liver disease drug
Shares of drug developer Kezar Life Sciences KZR.O rise 4.3% to $4.82 in extended trading
The U.S. FDA has lifted a partial clinical hold on company's mid-stage trial of evaluating zetomipzomib for the treatment of autoimmune hepatitis, a rare chronic liver disease
Zetomipzomib is a first-in-class selective immunoproteasome inhibitor designed to reduce inflammation without suppressing the immune system
Kezar has shifted its focus to autoimmune hepatitis after suspending development of zetomipzomib in lupus nephritis — a condition that causes inflammation and damage in the kidneys due to a form of immune-related condition called lupus
Company also exploring options to lift a clinical hold on zetomipzomib in lupus nephritis, based on recommendations from an independent committee
Shares down 31% YTD
Related Articles
Geopolitical Disruptions, OPEC+ and Russia’s Oil Production Game, 2026 International Crude Oil Price Trends?
TradingKey - For international investors, global crude oil prices serve not only as a "barometer" of the world economy and a "touchstone" for geopolitics, but also as investment opportunities and risk signals to be captured. The 2026 crude oil market is confronting a structural challenge characterized by a "supply-demand mismatch." Although geopolitical conflicts occasionally trigger periodic surges, U.S. production expansion, the OPEC+ market share battle, and slowing global economic growth inject further uncertainty into the trajectory of international oil prices for 2026.
SoundHound Analysis: Will This Overlooked AI Stock Be the Surprise Winner of 2026?
While buying SoundHound stock, you may need to look at key indicators that will help you tell the noise from the signals.
Stock Market Crash 2026: What Fed Signals and Economic Data Mean for Investors
TradingKey - The possibility of a stock market crash occurring in 2026 is becoming increasingly likely as investor sentiment continues to decline.
